Filgrastim (G-CSF)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-FILGRASTIM |
|---|---|
| Type | Drug |
| Aliases | FilgrastimGranixNeupogenZarxioФілграстим |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-BURKITT |
| Sources | SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | Recombinant human granulocyte colony-stimulating factor |
|---|---|
| Mechanism | Stimulates production, maturation, and release of neutrophils from bone marrow. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Indicated for primary prophylaxis of febrile neutropenia in regimens with >20% FN risk (e.g., R-CHOP in elderly), or secondary prophylaxis after FN episode.
Used By
Regimens
REG-CODOX-M-IVAC- CODOX-M / IVAC alternating × 4 (Magrath protocol)REG-FN-EMPIRICAL-ANTIBACTERIAL- Febrile neutropenia empirical antibacterial therapy (high-risk MASCC <21 OR ANC <100)
Supportive Care
SUP-G-CSF-PRIMARY-PROPHYLAXIS-PROSTATE- Primary G-CSF prophylaxis for ARASENS triplet (prostate)SUP-GCSF-NEUTROPENIA- G-CSF support for neutropenia